A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2020-03-27
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, open-label, multicenter study to evaluate the safety and
efficacy of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in
subjects with relapsed or refractory acute myeloid leukemia.